Fimea invites experts in cancer treatment to comment on the high-risk medicines classification of cancer drugs between 5 and 25 January 2026

Fimea’s National High-Risk Medicines Classification supports medication safety and contains key high-risk medicines and descriptions of the key risks associated with the medicines. The classification was published in April 2023 and it is currently integrated with databases such as FimeaWeb and Duodecim’s medicine database (in Finnish).

At the moment, Fimea is developing the high-risk classification of cancer drugs together with stakeholder groups. Preliminary content of the classification has been prepared by an expert group that includes experts in cancer treatment from the Wellbeing Services County of Pirkanmaa (Pirha) and Helsinki University Hospital (HUS). Now, Fimea invites healthcare professionals specialising in the treatment of cancer to comment on the preliminary content. The experts are asked to assess the cancer drugs included in the classification, the key risks and severe adverse reactions associated with the medicines as well as the key risks of the medication process (planning and prescribing medication, dosing, monitoring and patient guidance / medication counselling).

The aim is to ensure that the content has been prepared as comprehensively as possible with regard to the following:

• The available data sources
• Various risks and situations associated with the use and administration of medicines
• Clear and comprehensible language
• Usability when integrated with social and health care information systems 

Experts in cancer treatment and cancer drugs (doctors, nurses or pharmacists) are now invited to comment on the preliminary content of the classification. Three weeks have been reserved for commenting between 5 and 25 January 2026. Before commenting, the experts should familiarise themselves with the classification description, which explains the background and purpose of the classification. Comments are made under the expert’s own name on the Howspace platform, a link to which can be obtained by contacting Elsi Similä. The working group that prepares the classification will evaluate the comments and use them, where applicable, in finalising the content of the classification. The classification will be published in 2026 on the National High-Risk Medicines Classification website, and a separate announcement will be made regarding the publication. 

More information:

National Risk Medicines Classification